公司资料
PROCEPT BioRobotics 股价、新闻与催化剂
- 股票代码:
- PRCT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
21.09 USD (-2.59%)
收盘价
最后更新: 2026年8月17日
1.52B USD
市值
股价为何变动
Following the latest company update, “PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026”, PRCT closed down 2.59% at $21.09 on Aug 17, 2026. The move occurred in the trading session associated with this conference / presentation update.
公司概览
Urology Robotics
PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia. Its technology is designed to standardize tissue removal while preserving outcomes across different prostate sizes and anatomies.
Aquablation Therapy
Aquablation uses a robotically controlled, heat-free waterjet to remove obstructive prostate tissue. The procedure is planned from imaging and is intended to reduce dependence on surgeon technique compared with manually executed resection.
HYDROS Platform
The HYDROS Robotic System is the company’s current AI-enabled platform for Aquablation. Its FirstAssist AI software supports personalized image-guided planning, while recurring handpiece sales create a procedure-linked revenue stream alongside capital-system placements.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。